Swiss-based start-up Isospec Analytics has raised $1.9 million in pre-seed funding to further develop its biomolecular analysis technology. The company, founded by Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, is focused on identifying small molecules in blood samples to provide early insights into disease mechanisms. Isospec’s innovative technology allows for the identification of a larger number of molecules in a blood sample, providing quick results in hours rather than weeks or months, as with conventional techniques.
Isospec uses insights from analytical chemistry, photonics, and cryogenic materials to identify molecules in blood samples. The company is already providing molecular identification services to customers in Europe, the US, and Japan, highlighting the early commercialization efforts of the startup. In addition to identifying molecules, Isospec is working with hospitals and research institutes to develop diagnostic tests based on the data gathered from blood samples, with the ultimate goal of offering rapid diagnoses of health problems and diseases at an early stage of progression.
The company’s technology aims to not only accelerate diagnosis but also aid in the development of new drugs and treatments by understanding disease progression at an early stage. Isospec plans to expand its testing capacity by investing in automation technologies and software engineering, and is considering alternative commercial models, such as working independently as a diagnostic service or licensing its intellectual property to pharmaceutical and biotechnology companies.
The pre-seed funding for Isospec comes from Founderful, with additional participation from Tiny.vc and Venture Kick. The value proposition of Isospec’s technology, which offers early access to cutting-edge research in biomolecular analysis, has convinced investors of its potential. The founders believe that the technology has the potential to significantly impact the lives of millions of people by identifying critical biomarkers for diseases such as cancer, Alzheimer’s, and diabetes.
Despite the need for regulatory approvals and further development, Isospec expects to offer its technology as a complementary diagnostic tool within the next year. By identifying disease biomarkers in blood samples, the company aims to revolutionize early diagnosis and treatment of various health conditions. The founders see their work as not just creating a successful business, but also as a way to make a lasting impact on healthcare and improve the lives of individuals worldwide.
